Drug intelligence / Profile preview

Pandemic Bird Flu Vaccine

Development stage: Preclinical
Lead developer: Vaxine
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal

Overview

**Pandemic Bird Flu Vaccine** is a Vaxine development-stage pandemic avian-influenza vaccine program. It combines a protein-based influenza vaccine antigen with Vaxine's Advax adjuvant to enhance protective humoral and cellular immune responses against a potential pandemic influenza virus. The program was listed by Vaxine with Protein Sciences and Sanofi Pasteur as partners and was intended for prevention of pandemic influenza caused by bird-flu viruses.

Targets

BCR (Immunoglobulin G B Cell Receptor)TCR-H5-HA (T-cell receptor specific for H5 hemagglutinin-derived peptides)

Beyond the preview

Go deeper on Pandemic Bird Flu Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pandemic Bird Flu Vaccine.

Explore the full profile